Hepatitis Clinical Trials

Showing 1981-2000 of 2,113 trials

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

NCT01178996

The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic hepatitis C (CHC) already treated with, and not responding to previous courses of PEGIFN alpha plus RBV combination therapy, in comparison with a concurrent group treated with PEG IFN alpha2a in combination with RBV and placebo.

Chronic Hepatitis C

sigma-tau i.f.r. S.p.A.552 participantsStarted Dec 2004

Paris, France • Tübingen, Germany • Ioannina, Greece +6 more locations

UNKNOWNPhase 1

A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.

NCT01164384

Erstes Safety Trial mit Baminercept in chronischen HCV Patienten. Untersuchung des potentiell antiviralen, antiinflammatorischen Effekts sowie Modulation der hepatischen Gen-Expression. 10 Patienten, open label, 10 Wochen Therapie. Sequentielles Enrollement der ersten 4 Patienten. * Trial with medicinal product

Chronic HCV Hepatitis C

University of ZurichStarted Oct 2010

Zurich, Switzerland

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.

Related Searches

Transoral Endoscopic Liver Biopsy During Laparoscopic Gastric Bypass

Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)

Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection

Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy

TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

Antiviral Activity of AZD7295 in HCV Carriers

Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure

Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma

Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

Health Promotion and Management for Hepatitis B Carriers

Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

Continue Entecavir Rollover From China

Treatment of Cholestatic Pruritus With Sertraline